LATEST NEWS

22

June

ZipLine Medical Closes $9 Million Growth Financing Led by Existing Investor MVM Partners LLP

ZipLine Medical, Inc. today announced completion of a growth financing round totaling $9 million.

Read More

04

June

Ronald Lloyd Announced as New President and CEO of Aziyo Biologics

Seasoned leader brings a wealth of experience in commercial and business development

Read More

03

April

Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes

Lake Oswego, OR. and Silver Springs, MD. / PRNewswire

BIOTRONIK US and Aziyo today announced a strategic agreement allowing BIOTRONIK to distribute Aziyo’s CanGaroo® extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States. BioEnvelope will be available from BIOTRONIK starting in April 2018.

Read More

26

March

TELA Bio Announces Investment Agreement with ProMedica Innovations Venture Fund

TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that ProMedica, a mission-based, not-for-profit healthcare organization serving northwest Ohio and southern Michigan, has agreed to invest $1 million in TELA Bio through the ProMedica Innovations Venture Fund.

Read More

20

March

ONGOING ASSESSMENT OF FLUID RESPONSIVENESS IMPROVES CLINICAL OUTCOMES IN SEPTIC PATIENTS

Data leveraging Cheetah technology to be presented at the International Symposium on Intensive Care and Emergency Medicine in Brussels

Read More

12

March

TELA Bio Announces Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction

TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that data from a retrospective study evaluating the use of RBSs in abdominal wall reconstruction (AWR) procedures show low recurrence and complication rates.

Read More

27

February

COST OF SEVERE SEPSIS AND SEPTIC SHOCK TREATMENT REDUCED BY OVER $14,000 PER PATIENT WITH CHEETAH MEDICAL TECHNOLOGY

Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management devices, today announced the first presentation of major economic data showing total cost savings of over $1.4 million during a 6-month study in severe sepsis and septic shock patients.

Read More

25

February

NEW STUDY SHOWS IMPROVED PROTOCOL REDUCED SEPSIS MORTALITY RATE BY 85 PERCENT

Sutter Solano Medical Center, in collaboration with Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management technology, today announced the presentation of new study results at the Society of Critical Care Medicine’s 47th Annual Critical Care Congress in San Antonio, Texas.

Read More

16

February

Aziyo and Cook Biotech Announce Further Expansion of the Bio Envelope Franchise into Additional Markets

Aziyo Biologics, Inc. and Cook Biotech Inc. today announced the expansion of the Aziyo Bio Envelope franchise by entering into additional exclusive global license agreements expanding the applications for the Bio Envelope product into the field of neuromodulation.

Read More

03

November

Zip Surgical Skin Closure Preferred over Staples During Bilateral Knee Surgery

ZipLine® Medical, Inc. today announced results from the first study to assess Zip® Surgical Skin Closure versus surgical staples for closure in the same patients. Results were presented today as a poster at the American Academy of Hip and Knee Surgery Annual Meeting (AAHKS) by Rodney Benner, MD, of the Shelbourne Knee Center in Indianapolis.

Read More

31

October

Protected: Confidential: HighCape Partners Annual Meeting – October 2017

There is no excerpt because this is a protected post.

Read More

30

October

TELA Bio Announces Hiring of Greg Firestone as Vice President of Strategic Customer Relations

TELA Bio, Inc., a surgical reconstruction company leading the development of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that Greg Firestone has joined the company as vice president of strategic customer relations.

Read More

25

October

NEW STUDY DEMONSTRATES THE NEED FOR GUIDED INTRAOPERATIVE FLUIDS TO IMPROVE PATIENT OUTCOMES

Cheetah Medical, a Massachusetts based leader in non-invasive hemodynamic monitoring, announced new research results presented today at the American Society of Anesthesiologists Annual Meeting in Boston: Fluid Administration and Hospital Practice in Major Abdominal Procedures, Results from Examination of a Large Administrative Database.

Read More

25

October

Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has committed to invest up to $25 million in TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex™ portfolio of products for ventral hernia repair and abdominal wall reconstruction.

Read More

16

October

Protected: Confidential: Cybrexa Therapeutics Update – October 16, 2017

There is no excerpt because this is a protected post.

Read More

20

September

Recently Published Sepsis Study Supports Using Stroke Volume for Guiding Fluid Resuscitation Strategies While Reducing ICU Length of Stay by 33%

Cheetah Medical, a Massachusetts based leader in non-invasive hemodynamic monitoring, announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock.

Read More

18

September

Zip Surgical Skin Closure Reduces Post-Discharge Costs, Clinic Calls and Antibiotics in First Economic Study of Device

ZipLine Medical, Inc. today announced results from an economic study that showed that Zip Surgical Skin Closure reduced post-discharge costs for total knee arthroplasty (TKA) when compared to staples. Results were presented Friday at the Knee Society Members Meeting by Roger Emerson, MD, of the Texas Center for Joint Replacement, Plano, Texas.

Read More

06

June

ZipLine Medical Secures $12 Million in New Financing Led by New Investor, HighCape Partners

ZipLine Medical, Inc. today announced it completed a $12 million Series E round of financing. Proceeds from the financing will be used to continue worldwide commercialization activities for its Zip® Surgical Skin Closure products, as well as development of advanced tools to reduce post-discharge costs in a bundled care environment.

Read More

05

June

TELA Bio to Present Surgeon Feedback from Initial Clinical Experience with OviTex™ Reinforced BioScaffolds and Product Permeability Data at Abdominal Wall Reconstruction Conference

TELA Bio, Inc., a surgical reconstruction company leading the development of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company will present at the MedStar Georgetown University Hospital’s Abdominal Wall Reconstruction (AWR) Conference being held June 8-10 at the JW Marriott in Washington, D.C.

Read More

31

May

Aziyo Continues Building New Breed of Regenerative Medicine Company

Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced it has completed an asset purchase agreement with CorMatrix® Cardiovascular, Inc. for the purchase of all CorMatrix commercial assets and related intellectual property.

Read More

04

April

TELA Bio Initiates BRAVO Study of OviTex™ Reinforced BioScaffolds for Hernia Repair

ELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company has initiated a post-market clinical study, BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair (BRAVO), of its OviTex™ Permanent 1S device.

Read More

19

March

CHEETAH MEDICAL ANNOUNCES RESULTS OF KEY SEPSIS STUDY

Cheetah Medical, a rapidly growing medical device company, announced the results of a major new study conducted by Drs. Heath Latham and Steven Q. Simpson from the University of Kansas Medical Center. The study was designed to evaluate fluid resuscitation in ICU patients with severe sepsis and septic shock, and results were presented this week at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress in Brussels.

Read More

03

March

TELA Bio to Participate in 16th Annual Needham Healthcare Conference

TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, announced today that the company will participate in the 16th Annual Needham Healthcare Conference to be held April 4-5, 2017 at the Westin NY Grand Central Hotel in New York City.

Read More

19

December

CHEETAH MEDICAL ADVANCES THE SCIENCE OF FLUID MANAGEMENT

Cheetah Medical announced today that its eighth abstract on fluid management will be presented at Society of Critical Care Medicine meeting in January. Building on previous work, this abstract demonstrates a strong association between large volume fluid administration in septic shock and increased risk of death in more than 23,000 patients.

Read More

11

November

TELA Bio Announces Settlement of Litigation with LifeCell

TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that it has settled all litigations and disputes between TELA Bio and LifeCell, and that all pending state and federal court actions between the two companies have been dismissed. Terms of the agreement are confidential.

Read More

01

November

TELA Bio Announces OviTex™ Reinforced BioScaffolds Implanted in 100 Hernia Repair Procedures

TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company’s OviTex™ RBSs have been implanted in more than 100 hernia repair procedures since receiving U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2016.

Read More

10

October

Protected: HighCape Partners 2016 Annual Meeting

There is no excerpt because this is a protected post.

Read More

20

July

Cheetah Medical Announces Supplier Agreement with Allina Health

Cheetah Medical has signed a supplier contract with Allina Health, a leading non-for-profit healthcare system serving communities throughout Minnesota and western Wisconsin. The contract enables Allina Health facilities to have access to Cheetah Medical’s hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network.

Read More

13

July

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building block derived from ovine rumen, in layered constructs designed for multi-directional cell repopulation and healthy tissue remodeling.

Read More

13

July

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building block derived from ovine rumen, in layered constructs designed for multi-directional cell repopulation and healthy tissue remodeling.

Read More

15

June

Results from Studies of OviTex™ Reinforced BioScaffolds Presented at Abdominal Wall Reconstruction Conference

ELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that results from three studies of the company’s OviTex™ RBSs were presented at the Abdominal Wall Reconstruction (AWR) Conference held June 9-11 in Washington, D.C. OviTex RBSs combine synthetic and biologic materials by interweaving polymer through layers of intact extracellular matrix (ECM), a biologic building block derived from ovine rumen.

Read More

05

November

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company, Aziyo Biologics, Inc. HighCape has partnered with Tissue Banks International (TBI) to create a regenerative medicine company focused on best-in-class leadership and technology. Deerfield Management Co. joined HighCape in providing capital for the transaction.

Read More

05

November

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company, Aziyo Biologics, Inc. HighCape has partnered with Tissue Banks International (TBI) to create a regenerative medicine company focused on best-in-class leadership and technology. Deerfield Management Co. joined HighCape in providing capital for the transaction.

Read More

16

September

HighCape Partners Closes Initial $80 Million Growth Equity Fund

HighCape Partners Management, L.P. today announced the final closing of HighCape Partners, L.P., its initial $80 million growth equity fund focused on investing in commercial-stage life sciences companies.

Read More

21

August

Cheetah Medical Secures $5 Million Investment from HighCape Partners

Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013.

Read More

21

August

Cheetah Medical appoints Massachusetts General Hospital physician, Douglas M. Hansell, MD, MPH, as Chief Physician Executive

Cheetah Medical has appointed Douglas M. Hansell, MD, MPH, Assistant Clinical Professor of Anesthesia at Massachusetts General Hospital, as Chief Physician Executive.

Read More

21

August

Study* Shows $3+ of Costs Can Be Avoided by Hospitals for Every $1 They Spend During Surgery by Using Noninvasive Hemodynamic Monitoring

Cheetah Medical announced that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.

Read More

08

August

Cheetah Medical Expands Product Line, Introduces “Starling™ SV” Noninvasive Hemodynamic Monitoring System

Cheetah Medical has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasive hemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.

Read More

08

August

Cheetah Medical says its growth is outpacing global market for hemodynamic monitoring systems, expected to reach $1.1 billion by 2019, according to market research firm MarketsandMarkets

Cheetah Medical announced that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets.

Read More

19

May

CHEETAH MEDICAL INTRODUCES STARLING SV NONINVASIVE HEMODYNAMIC MONITORING SYSTEM

Cheetah Medical, a privately held and rapidly growing medical device company, announced today that it has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasivehemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.

Read More

19

March

CHEETAH MEDICAL SAYS ITS GROWTH IS OUTPACING GLOBAL MARKET FOR HEMODYNAMIC MONITORING SYSTEMS

Cheetah Medical, a privately held and rapidly growing medical device company, announced today that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets, the world’s No. 2 firm in terms of annually published premium market research reports.

Read More

19

January

DUKE UNIVERSITY STUDY SHOWS $3+ OF COSTS AVOIDED FOR EVERY $1 THEY SPEND USING NONINVASIVE HEMODYNAMIC MONITORING DURING SURGERY

Cheetah Medical, a rapidly growing medical device company, announced today that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.

Read More

19

October

KEY CLINICIANS RECOGNIZE THE CLINICAL AND ECONOMIC BENEFITS OF NONINVASIVE VOLUME MANAGEMENT

Cheetah Medical, a rapidly growing medical device company, announced today that key opinion leading physicians are recognizing the significant clinical and economic benefits of noninvasive hemodynamic monitoring during perioperative fluid management.

Read More

19

June

BOSTON BUSINESS JOURNAL SPEAKS TO CHEETAH MEDICAL CEO CHRIS HUTCHISON

Cheetah Medical Inc., a Newton-based company making non-invasive blood monitoring system, received $5 million in venture capitalist funding from HighCape Partners.

Read More

19

June

CHEETAH MEDICAL SECURES $5 MILLION INVESTMENT FROM HIGHCAPE PARTNERS

Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, today announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013. HighCape is a growth equity firm with a specialized focus and partner expertise in transforming commercial-stage life sciences companies into sustainable businesses.

Read More

CONTACT US

Could HighCape be the right partner for your growing business? Contact us for more information.